Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Streptococcus pneumoniae

Streptococcus pneumoniae

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Streptococcus pneumoniae

7 trials tracked for Streptococcus pneumoniae: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 82 citations.

7Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 1 1 Other / NA 1
  1. Phase 3 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease Completed · 82 cited
  2. Phase 3 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting Completed · 80 cited
  3. Phase 3 Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Completed · 36 cited
  4. Phase 3 Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ Completed · 18 cited
  5. Phase 3 Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age Completed
  6. Phase 1 Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults Completed
Show 1 more trials
  1. N/A Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Streptococcus pneumoniae: what the trials found

The pneumococcal conjugate vaccine (GSK1024850A) demonstrates significant efficacy in preventing culture-confirmed invasive pneumococcal disease (IPD) caused by any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life, a 3-dose primary course resulted in a person year rate of 0.000 compared to 0.564 in the control group (p<0.0001) [1, 3]. A 2-dose primary course also showed significant reduction in IPD rates, with 0.048 observed versus 0.564 in the control group (p=0.0009) [1, 3].

Clinical data regarding safety and immunogenicity for GSK1024850A indicate that the vaccine achieves seroprotection, with results showing 113 out of 360 subjects reaching anti-PRP levels above the 1.0 µg/mL cut-off 5. Safety profiles include recorded adverse events occurring within 7 days of vaccination 2 and specific counts of Grade 3 solicited local symptoms (ranging from 0 to 14) and general symptoms (ranging from 0 to 12) 4.

Recent results — preliminary, needs further review

  • GSK2231395A is currently under investigation but results are not yet corroborated.
  • A 7-valent vaccine injection is being studied, but findings are not yet corroborated.

For the clinician treating this condition

  • The pneumococcal conjugate vaccine (GSK1024850A) provides statistically significant protection against culture-confirmed IPD for the 10 target serotypes in infants starting vaccination within 7 months of life [1, 3].
  • Both a 3-dose and a 2-dose primary vaccination course are effective at reducing invasive disease rates compared to control groups [1, 3].
  • The vaccine demonstrates measurable seroprotection with anti-PRP levels exceeding the 1.0 µg/mL threshold 5.

AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days
Pediatrics RCT
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days Flu vaccine may increase bacteria levels in children and families
This randomized controlled trial of 405 families in the UK found that early live attenuated influenza vaccine (LAIV) significantly increased…
A new study shows that a specific flu vaccine can cause a temporary spike in bacteria that may spread to family members.
Oct 4, 2026
Azithromycin at discharge does not reduce pneumococcal carriage in Kenyan children
Pediatrics RCT
Azithromycin at discharge does not reduce pneumococcal carriage in Kenyan children A Single Dose Does Not Boost Drug Resistance
A randomized trial found a 5-day azithromycin course at hospital discharge did not lower pneumococcal carriage or resistance rates in Kenyan…
Giving a five-day course of azithromycin to children leaving the hospital did not increase drug resistance or change bacteria levels.
May 15, 2026
Prophylactic azithromycin during labor increases S. aureus resistance in mothers and infants
Pediatrics RCT
Prophylactic azithromycin during labor increases S. aureus resistance in mothers and infants Azithromycin in Labor Raises Short-Term Resistance Risk
This RCT sub-study of 911 women and 915 infants found that prophylactic oral azithromycin during labor increased azithromycin resistance in …
This could change how we balance infection protection and antibiotic safety in childbirth.
Apr 23, 2026